ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

16 links0 made here, not in the record38 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04801966Safety and Oversight of theIndividually TailoredTreatment Approach: A NovelPilot StudyPeter MacCallum Cancer Centre,NA · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSNeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSTrametinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCobimetinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedBinimetinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAlpelisibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionVemurafenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDabrafenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEncorafenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPalbociclibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedOlaparibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedRibociclibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAbemaciclibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionTalazoparibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Trametinib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Trametinib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2TrametinibClaude Opus 5.5TestedCurrent
Nov 2CobimetinibClaude Opus 5.5TestedReplaced
Nov 2BinimetinibClaude Opus 5.5TestedCurrent
Nov 2AlpelisibClaude Opus 5.5TestedReplaced
Nov 2VemurafenibClaude Opus 5.5TestedCurrent
Nov 2DabrafenibClaude Opus 5.5TestedCurrent
Nov 2EncorafenibClaude Opus 5.5TestedCurrent
Nov 2PalbociclibClaude Opus 5.5TestedReplaced
Nov 2OlaparibClaude Opus 5.5TestedReplaced
Nov 2RibociclibClaude Opus 5.5TestedReplaced
Nov 2AbemaciclibClaude Opus 5.5TestedReplaced
Nov 2TalazoparibClaude Opus 5.5TestedCurrent
Nov 2NivolumabClaude Opus 5.5TestedCurrent
Nov 2AtezolizumabClaude Opus 5.5TestedReplaced
Nov 2PembrolizumabClaude Opus 5.5TestedCurrent
Nov 3PalbociclibClaude Opus 5.5TestedCurrent
Nov 3OlaparibClaude Opus 5.5TestedCurrent
Nov 3RibociclibClaude Opus 5.5TestedCurrent
Nov 3AbemaciclibClaude Opus 5.5Background · optionCurrent
Nov 3AtezolizumabClaude Opus 5.5TestedCurrent
Nov 3CobimetinibClaude Opus 5.5TestedCurrent
Nov 3AlpelisibClaude Opus 5.5Background · optionCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18TrametinibRule based · role ruleTestedAgrees
Nov 18CobimetinibRule based · role ruleTestedAgrees
Nov 18BinimetinibRule based · role ruleTestedAgrees
Nov 18AlpelisibRule based · role ruleTestedOverridden
Nov 18VemurafenibRule based · role ruleTestedAgrees
Nov 18DabrafenibRule based · role ruleTestedAgrees
Nov 18EncorafenibRule based · role ruleTestedAgrees
Nov 18PalbociclibRule based · role ruleTestedAgrees
Nov 18OlaparibRule based · role ruleTestedAgrees
Nov 18RibociclibRule based · role ruleTestedAgrees
Nov 18AbemaciclibRule based · role ruleTestedOverridden
Nov 18TalazoparibRule based · role ruleTestedAgrees
Nov 18NivolumabRule based · role ruleTestedAgrees
Nov 18AtezolizumabRule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleTestedAgrees
As of nowNeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.